enGene Holdings Inc
ENGN
Company Profile
Business description
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Contact
4868 Rue Levy
Suite 220
Saint-LaurentQCH4R 2P1
CANT: +1 514 332-4888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
82
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,760.50 | 81.90 | 0.94% |
| CAC 40 | 7,743.92 | 17.72 | 0.23% |
| DAX 40 | 22,636.91 | 16.95 | -0.07% |
| Dow JONES (US) | 46,124.06 | 84.41 | -0.18% |
| FTSE 100 | 9,965.16 | 71.01 | 0.72% |
| HKSE | 25,063.71 | 681.24 | 2.79% |
| NASDAQ | 21,761.89 | 184.87 | -0.84% |
| Nikkei 225 | 53,857.78 | 1,605.50 | 3.07% |
| NZX 50 Index | 12,916.47 | 214.72 | 1.69% |
| S&P 500 | 6,556.37 | 24.63 | -0.37% |
| S&P/ASX 200 | 8,554.10 | 65.50 | 0.77% |
| SSE Composite Index | 3,881.28 | 0.00 | 0.00% |